Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 6 | Vintage Vibes

Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share in cash.

Benzinga

Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.

Benzinga

What Are Whales Doing With Amgen

Someone with a lot of money to spend has taken a bearish stance on Amgen (NASDAQ:AMGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Gold Tops 1,800; Alibaba Reports Upbeat Results

U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday

Benzinga

Why ChemoCentryx Is Trading Higher By 110%, Here Are 95 Stocks Moving In Thursday's Mid-Day Session

Gainers InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares jumped 178.5% to $12.45 after gaining over 12% on Wednesday.

Benzinga

Nasdaq Edges Higher; Crude Oil Falls Sharply

U.S. stocks pared some losses midway through trading, with the Nasdaq Composite turning higher on Thursday.

Benzinga

Dow Drops Over 100 Points; U.S. Trade Deficit Shrinks To This Level In June

U.S. stocks traded lower this morning, with the Dow Jones falling more than 100 points on Thursday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Benzinga Before The Bell: Alibaba's Delisting Concerns, Amgen's Potential $10.7B Tax Bill, Kenya Will Not Shut Facebook Services And Other Top Financial Stories Monday, August 1

CNBC

Benzinga

Amgen Whale Trades For July 12

Benzinga

Amgen is Our Growth Stock of the Week…

Biotech stocks are outperforming due to attractive valuations and strong catalysts. Amgen (AMGN) is one of the top stocks in the space due to its strong product portfolio, pipeline, and impressive management team. Read on to find out why it's our stock of the week.

StockNews.com

Check Out What Whales Are Doing With AMGN

Benzinga

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has risen 7.63% since its last report. The company recently reported that it has 20.30 million shares sold short, which is 3.81% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.97% on an annualized basis producing an average annual return of 10.41%. Currently, Amgen has a market capitalization of $130.40 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How Is The Market Feeling About Amgen?

Amgen's (NASDAQ:AMGN) short percent of float has fallen 5.35% since its last report. The company recently reported that it has 18.85 million shares sold short, which is 3.54% of all regular shares that are available for trading.

Benzinga

$100 Invested In Amgen 20 Years Ago Would Be Worth This Much Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 20 years by 2.03% on an annualized basis producing an average annual return of 9.14%. Currently, Amgen has a market capitalization of $131.14 billion.

Benzinga

$100 Invested In Amgen 15 Years Ago Would Be Worth This Much

Amgen (NASDAQ:AMGN) has outperformed the market over the past 15 years by 3.74% on an annualized basis producing an average annual return of 10.5%. Currently, Amgen has a market capitalization of $136.00 billion.

Benzinga

Analyst Ratings for Amgen

Analysts have provided the following ratings for Amgen (NASDAQ:AMGN) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Peering Into Amgen's Recent Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 20.75 million shares sold short, which is 3.9% of all regular shares that are available for trading.

StockNews.com

2 Buy-Rated Dow Jones Stocks to Add to Your Portfolio Now

Investors’ concerns over a potential recession due to the Fed’s policy measures to control inflation wreaked havoc on the stock market over the past few weeks. However, the recovery of the major stock-market indexes in the last trading session indicates that the market could be leveling off. With the possibility…

Benzinga

Executives Sell More Than $220M Of 3 Stocks

US stock futures traded higher on this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

This Is What Whales Are Betting On Amgen

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 21 strange trades.

Benzinga

Analyzing Amgen's Short Interest

Amgen's (NASDAQ:AMGN) short percent of float has fallen 7.95% since its last report. The company recently reported that it has 22.52 million shares sold short, which is 4.05% of all regular shares that are available for trading.

Benzinga

Here's How Much $100 Invested In Amgen 10 Years Ago Would Be Worth Today

Amgen (NASDAQ:AMGN) has outperformed the market over the past 10 years by 1.04% on an annualized basis producing an average annual return of 12.67%. Currently, Amgen has a market capitalization of $124.75 billion.

Benzinga

Check Out What Whales Are Doing With AMGN

A whale with a lot of money to spend has taken a noticeably bearish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 18 strange trades.

1 … 4 5 6 7

People

Jaimini DesaiJaimini Desai

59 stories

Tigran Gambaryan

26 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.